HGD

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Retrieved on: 
Thursday, March 28, 2024
Other Health, Health, Science, Research, Oncology, Cancer, Incidence, Risk, Esophageal cancer, Patient, Education, Mayo Clinic, Hepatology, EAC, Exact sciences, DNA, MD, Division, HGD, FDA, Food, Medical device

“In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.

Key Points: 
  • “In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.
  • “In esophageal cancer, earlier screening and detection will provide an important advance, as we have seen in other cancers.
  • We are collaborating with Mayo Clinic to continue the development of the Oncoguard Esophagus test as a minimally invasive solution for earlier detection of EAC and its precursors.”
    The Oncoguard Esophagus test is currently under development and features of the test described above are outlining current development goals.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Wednesday, March 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

D’Ornano+Co. completes 120 assignments in high growth tech investment analysis, continuing strong growth trajectory

Retrieved on: 
Wednesday, December 13, 2023
Finance, Professional Services, Other Technology, Technology, Asset Management, DTC, Carbon, Traction, Investment, PSG, IPO, Software as a service, Growth, HGD, Infravia Capital Partners, Cryptocurrency, Food delivery

has continued its momentum and trajectory of growth in supporting investors assessing high growth tech investments, completing 120 assignments across the private markets, in one of the toughest years in tech to-date.

Key Points: 
  • has continued its momentum and trajectory of growth in supporting investors assessing high growth tech investments, completing 120 assignments across the private markets, in one of the toughest years in tech to-date.
  • Investments in high-growth tech assets are at a turning point, as growth has decelerated hindering companies from growing into their valuations.
  • “Many companies struggled this year and are overvalued based on their growth potential and quality of business fundamentals.
  • “There is a high bar, and we are well-positioned to help entrepreneurs build successful traction as they navigate and prepare for exit.

Castle Biosciences Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
General Health, Medical Devices, Other Health, Health, Medical Supplies, Adjustment, Laboratory, EAC, Metastasis, Innovation, The American Journal of Gastroenterology, Physician, Esophageal cancer, New York State Department of Health, EBITDA, Net, News, Cancer, GAAP, BE, Acquisition, Memorial Sloan Kettering Cancer Center, Sentinel lymph node, Workplace, Purpose, Risk, Compensation, Webcast, LGD, Question and Answer, Depreciation, HGD, Depression, American Journal, Table, Investment, Patient, Compensation and benefits, Pharmaceutical industry, Lithium, Video game, Film industry, Cryptocurrency, Clothing, Birth control, Medical imaging, Real estate

Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:

Key Points: 
  • Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:
    DecisionDx®-Melanoma test reports delivered in the quarter were 8,559, compared to 7,354 in the third quarter of 2022, an increase of 16%.
  • DecisionDx®-SCC test reports delivered in the quarter were 2,820, compared to 1,636 in the third quarter of 2022, an increase of 72%.
  • MyPath® Melanoma test reports delivered in the quarter were 1,011, compared to 834 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the third quarter of 2022, an increase of 21%.
  • Castle Biosciences will hold a conference call on Thursday, Nov. 2, 2023, at 4:30 p.m. Eastern time to discuss its third quarter 2023 results and provide a corporate update.

Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Tuesday, October 24, 2023
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, EAC, American College, IND, Identity, New York University Grossman School of Medicine, Medicare, Physician, ACG, Pathology, Cancer, BE, University School, Dysplasia, Geisinger Commonwealth School of Medicine, Risk, American College of Gastroenterology, LGD, HGD, Geisinger Medical Center, Diagnosis, Nursing, Medical imaging, Medicine

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.
  • “However, we find that at least half of the patients who progress to EAC come from this “low-risk” population, which tells us that there is a critical need to improve our risk-stratification of these patients.
  • In patients with higher-risk clinicopathologic factors (males with a pathology diagnosis of indefinite for dysplasia (IND) or LGD), TissueCypher identified low-risk patients with predicted progression rates similar to patients with NDBE.
  • Overall, the data show the risk stratification provided by the TissueCypher test can aid physicians and patients in making risk-aligned patient management decisions, such as escalated or de-escalated care, which may lead to improved health outcomes.

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

Retrieved on: 
Monday, October 2, 2023
Oncology, Health, Surgery, Managed Care, Research, Science, Biotechnology, LGD, AFS, Esophagus, Cancer, Radiofrequency ablation, EAC, Incidence, BE, HGD, Dysplasia, HIV disease progression rates, Patient, Physician, Risk, Report, Annual general meeting, Esophageal cancer, Poster, EET, RFA, Pharmaceutical industry, Medical imaging

The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.

Key Points: 
  • The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.
  • The poster, titled “A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center,” can be viewed here .
  • The case study reinforced the ability of TissueCypher to identify NDBE patients at high/intermediate risk for progression to HGD/EAC.
  • Identification of NDBE patients with similar progression risk to LGD enables physicians and their patients to consider risk-aligned upstaging of care to prevent development of EAC and improve their overall health outcomes.

TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Retrieved on: 
Thursday, September 14, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Research, Science, University, LGD, Marie Cassidy, SURF, Pathology, Cancer, Radiofrequency ablation, EAC, BE, HGD, Dysplasia, Patient, Standard of care, Physician, Surveillance, Esophageal cancer, Artificial intelligence, Diagnosis, Disease, Medical device, Medical imaging, Gastroenterology

The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.

Key Points: 
  • The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.
  • Use of the TissueCypher test in combination with pathology review identified 80.4% of patients who progressed, indicating that the test can increase the early detection of progressors when used with pathology.
  • Overall, the study demonstrated that TissueCypher can accurately predict progression to HGD or EAC in BE patients who are initially diagnosed with LGD in a community setting.
  • Further, TissueCypher test results can provide an objective solution to variable pathology review, allowing physicians to make more informed management decisions for their patients, which may include upstaging care for patients at high risk for progression and reducing unnecessary interventions in low-risk patients.

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

Retrieved on: 
Friday, September 8, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Male, Probability, LGD, Geisinger Medical Center, ISDE, Pathology, Cancer, Medicine, Geisinger Commonwealth School of Medicine, EAC, Congress, BE, HGD, Dysplasia, Physician, Risk, Diagnosis, IND, Pharmaceutical industry, Medical imaging, Patient

Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.

Key Points: 
  • Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.
  • Patients with NDBE are considered to be at low risk for progression based on their clinical risk factors.
  • These data demonstrate that TissueCypher provided impactful risk stratification, independent of clinicopathologic risk factors, to enable risk-aligned management of BE patients.
  • This included objective information to support surveillance-only management for patients with a low risk of progression and escalated surveillance/treatment for patients at high risk of progression.

Pitchbook Names D’Ornano + Co. #1 M&A Advisor in France

Retrieved on: 
Wednesday, August 23, 2023
Consulting, Accounting, Professional Services, Other Professional Services, Legal, IPO, HGD, VC, Partner (business rank), Risk management

HGD leverages detailed business model analysis to validate both the intrinsic value of the business as well as its resilience.

Key Points: 
  • HGD leverages detailed business model analysis to validate both the intrinsic value of the business as well as its resilience.
  • In the past six months D’Ornano + Co. has advised on several industry-defining deals across Europe and the U.S. for the world’s largest investors.
  • This advantage allows for superior insight into untested business models’ success trajectory and supports identifying risks faster.
  • “Our consistent rise through Pitchbook’s league tables underscores the need for a new way of analyzing disruptive technologies and business models.

Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

Retrieved on: 
Friday, May 26, 2023
Oncology, Health, Other Science, General Health, Clinical Trials, Science, Biotechnology, Abstract, LGD, Research, SOC, EAC, DDW, BE, HGD, Dysplasia, Poster, Patient, Standard of care, Physician, Risk, EET, IND, Nursing, Medical imaging, Gastroenterology, Distinction

Full-text abstracts will be published in the May online supplement to Gastroenterology; the posters are available on the DDW ePosters site under Posters of Distinction category, Esophageal Diseases .

Key Points: 
  • Full-text abstracts will be published in the May online supplement to Gastroenterology; the posters are available on the DDW ePosters site under Posters of Distinction category, Esophageal Diseases .
  • TissueCypher risk-stratified patients in each pathologic (non-dysplastic BE (NDBE), indefinite for dysplasia (IND) and low-grade dysplasia (LGD)) and clinicopathologic (females, males, short-segment BE and long-segment BE) subset.
  • Overall, the study data indicate that TissueCypher’s objective risk-stratification has significant, independent clinical utility to improve management decisions for BE patients in surveillance.
  • Management decisions were then simulated using the real-world diagnoses with expert review of LGD, with or without guidance from TissueCypher test results.